QSM and Regional DCE MRI Permeability Using GOCART Technique

Withdrawn before enrolling

Conditions studied: Intracranial Neoplasm

In brief

This randomized pilot clinical trial studies quantitative susceptibility mapping (QSM) and regional dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) permeability using golden-angle cartesian randomized time-resolved (GOCART) technique in evaluating regional gadolinium retention in the brain in patients with intracranial neoplasm receiving gadobenate dimeglumine or gadoterate meglumine. MRI diagnostic techniques such as, QSM and DCE MRI, may help to gather information regarding brain changes associated with gadolinium deposits during 8 to 18 months after administration of gadobenate dimeglumine or gadoterate meglumine.

Key facts

Study ID

NCT03091803

Run by

University of Southern California

People needed

0

Starts

2017-04-04

Expected to finish

2021-04-04

Last updated by the study team

2021-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients)
• Willingness to comply with the study protocol

You may not qualify if…

• Contraindications for MRI or GBCA (standard of care)
• Abnormal renal function with estimated glomerular filtration rate (eGFR) less than 30 mL/min/m\^2 based on creatinine obtained within last 30 days
• History of previous administration of GBCA

Where it is running

• USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.